Bevacizumab side effects: what 123,107 FDA adverse event reports show

Bevacizumab · Avastin · 1,301 reaction terms · 375,061 drug–reaction co-reports · data 2026-09-14

Drug class

Vascular Endothelial Growth Factor Inhibitor

FDA label (Established Pharmacologic Class) · compare the class

Brand names

Avastin

openFDA label

Who reports

123,107 reports · 91% serious · 28,193 with death outcome · 54% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal c.

FDA label, Indications and Usage

What it is

Bevacizumab is a vascular endothelial growth factor inhibitor. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab has an approximate molecular weight of 149 kDa.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 6Labeled (related wording) 11Likely indication confounding 9Reporting / coding artifact 2Not in label — unassessed 12

What the badges mean

Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1,261 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Suspected transmission of an infectious agent via product	505	118.3 105.6–132.6ROR 118.8 · χ² 34,324 / p <1e-300	69.5 EB05 64.6 · IC025 +5.9 3/3 methods agree	Labeled (related wording) related wording	serious n=504	not reported in cached trials
Tumour perforation	119	105.7 84.1–133.0ROR 105.9 · χ² 7,497 / p <1e-300	64.5 EB05 55.3 · IC025 +5.4 3/3 methods agree	Labeled (related wording) related wording	serious n=119 · ♀ 26% (drug 54%) · 100% clinician	not reported in cached trials
Bacterial endophthalmitis	82	81.1 62.3–105.5ROR 81.1 · χ² 4,312 / p <1e-300	54.3 EB05 45.1 · IC025 +5.0 3/3 methods agree	Not in label — unassessed	serious n=81 · 100% clinician	not reported in cached trials
Urogenital fistula	68	69.7 52.5–92.5ROR 69.7 · χ² 3,200 / p <1e-300	48.8 EB05 39.8 · IC025 +4.8 3/3 methods agree	Not in label — unassessed	serious n=67 · ♀ 100% (drug 54%) · 100% clinician	not reported in cached trials
Radiation necrosis	155	63.6 52.9–76.5ROR 63.7 · χ² 6,874 / p <1e-300	46.1 EB05 40.3 · IC025 +5.1 3/3 methods agree	Labeled (related wording) related wording	serious n=153 · 94% clinician	not reported in cached trials
Gastrointestinal perforation	1,090	60.5 56.5–64.8ROR 61.1 · χ² 46,802 / p <1e-300	44.7 EB05 42.5 · IC025 +5.4 3/3 methods agree	Labeled adverse reaction exact term	serious n=1,082 · 93% clinician	NCT00112918: 1/1,145 (0.1%) on Bevacizumab (serious AE)
Colorectal cancer metastatic	567	56.0 50.9–61.6ROR 56.3 · χ² 22,906 / p <1e-300	42.1 EB05 39.3 · IC025 +5.2 3/3 methods agree	Likely indication confounding term in indications; also in warnings	serious n=564 · 93% clinician	not reported in cached trials
Hepatic atrophy	107	53.0 42.7–65.9ROR 53.1 · χ² 4,107 / p <1e-300	40.2 EB05 34.2 · IC025 +4.8 3/3 methods agree	Not in label — unassessed	serious n=107 · ♀ 100% (drug 54%) · 100% clinician	not reported in cached trials
Rectal perforation	127	52.3 42.8–63.8ROR 52.3 · χ² 4,825 / p <1e-300	39.8 EB05 34.3 · IC025 +4.8 3/3 methods agree	Labeled (related wording) related wording	serious n=127 · 100% clinician	NCT00112918: 1/1,145 (0.1%) on Bevacizumab (serious AE)
Pseudocirrhosis	72	47.7 36.7–62.0ROR 47.8 · χ² 2,526 / p <1e-300	37.0 EB05 30.4 · IC025 +4.5 3/3 methods agree	Not in label — unassessed	serious n=72 · ♀ 100% (drug 54%) · 100% clinician	not reported in cached trials
Diabetic retinal oedema	108	45.7 36.9–56.5ROR 45.7 · χ² 3,671 / p <1e-300	35.9 EB05 30.5 · IC025 +4.6 3/3 methods agree	Not in label — unassessed	serious n=106	not reported in cached trials
Retinal pigment epithelial tear	139	43.6 36.2–52.5ROR 43.6 · χ² 4,552 / p <1e-300	34.6 EB05 30.0 · IC025 +4.7 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=138 · 100% clinician	not reported in cached trials
Endophthalmitis	1,199	42.4 39.8–45.2ROR 42.8 · χ² 38,665 / p <1e-300	34.0 EB05 32.4 · IC025 +5.0 3/3 methods agree	Not in label — unassessed	serious n=1,179 · 91% clinician	not reported in cached trials
Anastomotic leak	139	42.4 35.2–51.0ROR 42.4 · χ² 4,446 / p <1e-300	33.9 EB05 29.4 · IC025 +4.6 3/3 methods agree	Not in label — unassessed	serious n=138 · ♀ 34% (drug 54%) · 100% clinician	NCT00433511: 1/1,168 (0.1%) on Bevacizumab (serious AE)
Detachment of retinal pigment epithelium	171	41.5 35.1–49.0ROR 41.5 · χ² 5,377 / p <1e-300	33.3 EB05 29.3 · IC025 +4.7 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=170	not reported in cached trials
Subretinal fluid	207	41.4 35.6–48.2ROR 41.5 · χ² 6,510 / p <1e-300	33.3 EB05 29.7 · IC025 +4.7 3/3 methods agree	Not in label — unassessed	serious n=205 · 100% clinician	not reported in cached trials
Tumour necrosis	194	38.4 32.9–44.9ROR 38.5 · χ² 5,722 / p <1e-300	31.4 EB05 27.8 · IC025 +4.6 3/3 methods agree	Labeled (related wording) related wording	serious n=194	not reported in cached trials
Protein urine	151	34.0 28.5–40.5ROR 34.0 · χ² 3,991 / p <1e-300	28.3 EB05 24.7 · IC025 +4.4 3/3 methods agree	Labeled (related wording) related wording	serious n=143	not reported in cached trials
Anastomotic complication	58	33.6 25.4–44.6ROR 33.7 · χ² 1,502 / p <1e-300	27.9 EB05 22.4 · IC025 +4.1 3/3 methods agree	Reporting / coding artifact	serious n=58 · ♀ 0% (drug 54%) · 100% clinician	not reported in cached trials
Glioblastoma	275	33.4 29.3–38.0ROR 33.5 · χ² 7,174 / p <1e-300	27.9 EB05 25.3 · IC025 +4.5 3/3 methods agree	Likely indication confounding term in indications; also in warnings	serious n=272	not reported in cached trials
Proteinuria	3,066	33.0 31.7–34.2ROR 33.8 · χ² 79,398 / p <1e-300	27.7 EB05 26.9 · IC025 +4.7 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 18.0 · 94% clinician	NCT00433511: 20/1,168 (1.7%) on Bevacizumab (serious AE)
Nasal septum perforation	105	32.8 26.6–40.5ROR 32.9 · χ² 2,683 / p <1e-300	27.5 EB05 23.4 · IC025 +4.3 3/3 methods agree	Labeled adverse reaction exact term	serious n=97 · ♀ 75% (drug 54%)	not reported in cached trials
Rectal cancer metastatic	56	32.7 24.6–43.6ROR 32.7 · χ² 1,413 / p <1e-300	27.3 EB05 21.8 · IC025 +4.0 3/3 methods agree	Likely indication confounding term in indications; also in warnings	serious n=56 · ♀ 0% (drug 54%) · 100% clinician	not reported in cached trials
Bleeding varicose vein	85	31.6 25.0–39.8ROR 31.6 · χ² 2,090 / p <1e-300	26.6 EB05 22.2 · IC025 +4.2 3/3 methods agree	Labeled adverse reaction exact term	serious n=85 · ♀ 0% (drug 54%) · 100% clinician	not reported in cached trials
Ovarian cancer recurrent	245	30.7 26.8–35.1ROR 30.7 · χ² 5,915 / p <1e-300	26.0 EB05 23.4 · IC025 +4.4 3/3 methods agree	Likely indication confounding term in indications; also in warnings	serious n=241 · ♀ 100% (drug 54%)	not reported in cached trials
Glioma	96	29.9 24.0–37.1ROR 29.9 · χ² 2,248 / p <1e-300	25.4 EB05 21.4 · IC025 +4.2 3/3 methods agree	Not in label — unassessed	serious n=95 · ♀ 0% (drug 54%) · 100% clinician	not reported in cached trials
Gastrointestinal anastomotic leak	55	27.6 20.7–36.7ROR 27.6 · χ² 1,187 / p 2e-260	23.7 EB05 18.9 · IC025 +3.9 3/3 methods agree	Labeled (related wording) related wording	serious n=54 · ♀ 0% (drug 54%) · 100% clinician	not reported in cached trials
Small intestinal perforation	259	27.1 23.8–30.9ROR 27.2 · χ² 5,582 / p <1e-300	23.4 EB05 21.1 · IC025 +4.3 3/3 methods agree	Labeled (related wording) related wording	serious n=259 · 93% clinician	NCT00112918: 4/1,145 (0.3%) on Bevacizumab (serious AE)
Perforation	108	26.7 21.8–32.7ROR 26.7 · χ² 2,277 / p <1e-300	23.0 EB05 19.6 · IC025 +4.1 3/3 methods agree	Labeled adverse reaction exact term	serious n=104 · 100% clinician	NCT00433511: 1/972 (0.1%) control (serious AE)
Optical coherence tomography abnormal	89	26.6 21.3–33.3ROR 26.6 · χ² 1,869 / p <1e-300	23.0 EB05 19.2 · IC025 +4.0 3/3 methods agree	Reporting / coding artifact	serious n=89 · 100% clinician	not reported in cached trials
Oesophageal varices haemorrhage	290	26.1 23.1–29.5ROR 26.1 · χ² 6,031 / p <1e-300	22.7 EB05 20.6 · IC025 +4.3 3/3 methods agree	Labeled adverse reaction exact term	serious n=289 · ♀ 17% (drug 54%) · 97% clinician	not reported in cached trials
Tumour rupture	73	25.8 20.2–33.0ROR 25.8 · χ² 1,485 / p <1e-300	22.4 EB05 18.4 · IC025 +3.9 3/3 methods agree	Labeled (related wording) related wording	serious n=73 · ♀ 0% (drug 54%) · 100% clinician	not reported in cached trials
Ileal perforation	82	23.8 18.9–30.0ROR 23.8 · χ² 1,549 / p <1e-300	20.9 EB05 17.4 · IC025 +3.9 3/3 methods agree	Not in label — unassessed	serious n=82 · 100% clinician	NCT00112918: 1/1,145 (0.1%) on Bevacizumab (serious AE)
Cataract nuclear	81	23.8 18.9–30.1ROR 23.8 · χ² 1,530 / p <1e-300	20.9 EB05 17.3 · IC025 +3.9 3/3 methods agree	Not in label — unassessed	serious n=79 · 90% clinician	not reported in cached trials
Tumour haemorrhage	349	23.7 21.1–26.5ROR 23.7 · χ² 6,614 / p <1e-300	20.8 EB05 19.1 · IC025 +4.2 3/3 methods agree	Labeled (related wording) related wording	serious n=349 · ♀ 32% (drug 54%) · 94% clinician	not reported in cached trials
Metastases to peritoneum	306	23.6 20.9–26.6ROR 23.7 · χ² 5,784 / p <1e-300	20.8 EB05 18.9 · IC025 +4.1 3/3 methods agree	Likely indication confounding shares a disease stem with the indications wording	serious n=305	not reported in cached trials
Duodenal perforation	118	23.4 19.3–28.4ROR 23.4 · χ² 2,201 / p <1e-300	20.6 EB05 17.7 · IC025 +3.9 3/3 methods agree	Not in label — unassessed	serious n=117 · 91% clinician	not reported in cached trials
Ovarian cancer metastatic	102	23.4 19.0–28.8ROR 23.4 · χ² 1,899 / p <1e-300	20.6 EB05 17.4 · IC025 +3.9 3/3 methods agree	Likely indication confounding term in indications; also in warnings	serious n=101 · ♀ 100% (drug 54%)	not reported in cached trials
Reversible posterior leukoencephalopathy syndrome	94	22.8 18.4–28.3ROR 22.8 · χ² 1,707 / p <1e-300	20.1 EB05 16.9 · IC025 +3.9 3/3 methods agree	Labeled (related wording) related wording	serious n=91 · ♀ 75% (drug 54%) · 100% clinician	NCT00112918: 1/1,135 (0.1%) on Bevacizumab (serious AE)
Colon cancer metastatic	183	21.8 18.7–25.4ROR 21.8 · χ² 3,195 / p <1e-300	19.4 EB05 17.1 · IC025 +4.0 3/3 methods agree	Likely indication confounding term in indications	serious n=182	not reported in cached trials

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Bevacizumab as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (8 of 40 signal terms matched).

NCT00433511 — Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients W (N=4994, PHASE3; 350 AE terms posted; arms: Arm A (Chemo + Placebo); Arm B (Chemo + Bevacizumab); Arm C (Chemo + Bevacizumab Then Bevacizu; Arm D (Bevacizumab Cycles 9-18 of Arm C))
NCT00112918 — Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High (N=3451, PHASE3; 384 AE terms posted; arms: FOLFOX4; FOLFOX4 + Bv; XELOX+Bv)

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Off label use (used outside approved label)	14,450	2.9 2.8–2.9ROR 3.1 · χ² 18,020 / p <1e-300	2.8 EB05 2.8 · IC025 +1.5 3/3 methods agree	Reporting / coding artifact	serious PRR 2.7	not reported in cached trials
Death	13,214	2.6 2.6–2.7ROR 2.8 · χ² 13,802 / p <1e-300	2.6 EB05 2.6 · IC025 +1.4 3/3 methods agree	Outcome field, not a reaction	serious PRR 1.7	NCT00433511: 1/1,168 (0.1%) on Bevacizumab (serious AE)
Disease progression	7,377	11.3 11.1–11.6ROR 12.0 · χ² 65,275 / p <1e-300	10.7 EB05 10.4 · IC025 +3.4 3/3 methods agree	Reporting / coding artifact	serious PRR 7.4	NCT00433511: 3/1,168 (0.3%) on Bevacizumab; 4/972 (0.4%) control (serious AE)
Diarrhoea (diarrhea)	7,349	2.0 1.9–2.0ROR 2.0 · χ² 3,506 / p <1e-300	1.9 EB05 1.9 · IC025 +0.9	Labeled adverse reaction exact term	serious PRR 2.1	NCT00433511: 11/1,168 (0.9%) on Bevacizumab; 29/972 (3.0%) control (serious AE)
Nausea	6,525	1.4 1.4–1.4ROR 1.4 · χ² 808 / p 5e-178	1.4 EB05 1.4 · IC025 +0.5	Labeled adverse reaction exact term	serious PRR 1.6	NCT00433511: 5/1,168 (0.4%) on Bevacizumab; 25/972 (2.6%) control (serious AE)
Fatigue (tiredness)	6,455	1.4 1.4–1.5ROR 1.4 · χ² 821 / p 8e-181	1.4 EB05 1.4 · IC025 +0.5	Labeled adverse reaction exact term	serious PRR 1.6	NCT00433511: 31/1,168 (2.7%) on Bevacizumab; 66/972 (6.8%) control (serious AE)
Hypertension (high blood pressure)	5,851	4.8 4.7–4.9ROR 5.0 · χ² 17,314 / p <1e-300	4.7 EB05 4.6 · IC025 +2.2 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 3.4	NCT00433511: 131/1,168 (11.2%) on Bevacizumab; 20/972 (2.1%) control (serious AE)
Vomiting	4,956	1.8 1.8–1.9ROR 1.8 · χ² 1,814 / p <1e-300	1.8 EB05 1.8 · IC025 +0.8	Labeled adverse reaction exact term	serious PRR 1.6	NCT00433511: 8/1,168 (0.7%) on Bevacizumab; 15/972 (1.5%) control (serious AE)
Anaemia (low red blood cells)	4,436	4.0 3.9–4.1ROR 4.1 · χ² 9,955 / p <1e-300	4.0 EB05 3.9 · IC025 +1.9 3/3 methods agree	Not in label — unassessed	serious PRR 2.7 · 90% clinician	NCT00433511: 5/1,168 (0.4%) on Bevacizumab; 15/972 (1.5%) control (serious AE)
Pyrexia (fever)	4,072	2.0 2.0–2.1ROR 2.0 · χ² 2,091 / p <1e-300	2.0 EB05 2.0 · IC025 +1.0	Labeled adverse reaction exact term	serious PRR 1.5	NCT00112918: 20/1,126 (1.8%) on Bevacizumab (serious AE)
Neutropenia (low neutrophils (infection-fighting cells))	4,015	5.2 5.0–5.3ROR 5.3 · χ² 13,188 / p <1e-300	5.0 EB05 4.9 · IC025 +2.3 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 3.3 · 94% clinician	NCT00433511: 4/1,942 (0.2%) on Bevacizumab; 6/972 (0.6%) control (serious AE)
Asthenia (weakness)	3,576	1.6 1.6–1.7ROR 1.6 · χ² 868 / p 5e-191	1.6 EB05 1.6 · IC025 +0.6	Labeled adverse reaction exact term	serious PRR 1.4	NCT00112918: 3/1,145 (0.3%) on Bevacizumab (serious AE)
Decreased appetite (loss of appetite)	3,458	2.6 2.5–2.7ROR 2.6 · χ² 3,291 / p <1e-300	2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 2.4	NCT00112918: 1/1,145 (0.1%) on Bevacizumab (serious AE)
Dyspnoea (shortness of breath)	3,404	1.0 1.0–1.1ROR 1.0 · χ² 2 / p 0.072	1.0 EB05 1.0 · IC025 -0.0 PRR-only: not supported by EBGM or IC	Labeled adverse reaction exact term	serious PRR 0.9	NCT00433511: 18/1,168 (1.5%) on Bevacizumab; 32/972 (3.3%) control (serious AE)
Thrombocytopenia (low platelets)	3,366	5.3 5.1–5.5ROR 5.4 · χ² 11,351 / p <1e-300	5.1 EB05 5.0 · IC025 +2.3 3/3 methods agree	Labeled adverse reaction exact term	serious PRR 3.3 · 92% clinician	NCT00112918: 1/1,135 (0.1%) on Bevacizumab (serious AE)

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

Bacterial endophthalmitis — n=82, PRR 81.1
Urogenital fistula — n=68, PRR 69.7
Hepatic atrophy — n=107, PRR 53.0
Pseudocirrhosis — n=72, PRR 47.7
Diabetic retinal oedema — n=108, PRR 45.7
Endophthalmitis — n=1,199, PRR 42.4
Anastomotic leak — n=139, PRR 42.4 (also seen in trial arm)
Subretinal fluid — n=207, PRR 41.4
Glioma — n=96, PRR 29.9
Ileal perforation — n=82, PRR 23.8 (also seen in trial arm)

✓ A hand-written Bradford Hill causality assessment exists for this drug: Bevacizumab ↔ Hypertension.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Bevacizumab?

In FDA FAERS, the most frequently co-reported reaction terms for Bevacizumab are diarrhoea, nausea, fatigue, hypertension, vomiting, anaemia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Bevacizumab have an FDA boxed warning?

No. The FDA label retrieved for Bevacizumab has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Bevacizumab causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 939b5d1f-9fb2-4499-80ef-0607aa6b114e, effective 20250106; matched on openfda.generic_name.exact:"BEVACIZUMAB" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 1,301 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath
ClinicalTrials.gov API v2 (query BEVACIZUMAB, results-bearing studies sorted by enrollment)

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.